P576 Endoscopic healing with vedolizumab in Crohn's disease occurs predominantly in the first 6 months and is independent of serum concentrations: Data from LOVE-CD

Abstract Background Endoscopic healing is an important treatment goal in Crohn’s disease (CD). Vedolizumab (VDZ) was shown to induce endoscopic after 6 months a significantly greater proportion of pts with early CD than those late (>2 years)(UEGW 2022). We investigated whether further could be attained more VDZ no SES-CD worsening at month compared baseline. Methods Pts the LOVE-CD study received standard doses and had ileocolonoscopies baseline, w26 52. studied kinetics improvement during continued treatment. Endoscopies were scored by independent readers. So far, 157 completed trial available central reading results. here report results 76 (48%) who stable diseases or any degree 3 centrally read endoscopy scores (baseline, 52) present. serum conc also measured correlated improvement. Results (mean age 36.7, 51 (67%) female, median baseline 10 (range 3-30) reached w52 w26. identified patterns: 1) 24 (32%, 12 early, CD) 7.5 3-21) score 0 Three these again mild lesions (SES-CD 1-4), rest maintained SES-CD=0 (endoscopic healing); 2) 20 (26%, 14 8 3-27) 1-3 remission defined as SES-CD<4). At w52, 10/20 0, 7/20 same only 3/20 higher score; 3) 32 (42%, 5 27 5-30) >4) drop 7 5-20) 0-15) w52. Figure 1 shows evolution SES-CD. The mean (1) 19.36 mg/l 22.23 group healing, (2) 19.52 21.69 remission, (3) 17.38 20.09 without remission. Conclusion In this subset unchanged w26, majority (44/76) (SES-CD<4). Overall, subgroup responders -1 25) points between w0 -10 +15) beyond unrelated conc.